Coronavirus Archives | Frier Levitt

Pharmacy ALERT: CVS Caremark Nearly Doubles Drugs on “Aberrant Quantities” Product List Effective January 2021

Dae Y. Lee, Esq., Pharm.D CPBS and Harini Bupathi, Esq. January 7, 2021

In 2019, Frier Levitt reported a new dispensing limitation CVS Caremark (“Caremark”) introduced in its retail networks that took effect on January 1, 2020. Specifically, Caremark issued an “Aberrant Product List” that identified... Read More

Billing for COVID-19 Testing at Pharmacies

Martha M. Rumore Pharm.D., Esq., John E. Morrone, Esq. and Christopher Caltavuturo, Esq. July 22, 2020

Pharmacy reimbursement issues and state imposed limits on pharmacist’s scope of practice have been major hurdles to increased COVID-19 testing at pharmacies. The Department of Health and Human Services has now intervened stating that federal... Read More

Blogs & Articles | COVID-19 Resources | Pharmacy Law

Right to Try and Right to Information More Important than Ever

Nicole M. DeWitt, Esq. June 16, 2020

With the imminent need for information on government action in regards to medical issues and potential lifesaving treatments during the Covid-19 pandemic, various state and federal agencies have seemingly dismissed the public’s right to... Read More

Blogs & Articles | COVID-19 Resources | Pharmacy Law

DHHS Provider Relief Funds- New Funding Round for Medicaid Providers Excluded from First Rounds of Funding

Marc H. Mayer, Esq. and Daniel B. Frier, Esq. June 11, 2020

On June 9, 2020 the U.S. Department Health and Human Services (“DHHS”) announced that it was allocating a total of $15 Billion in Provider Relief Fund payments to Medicaid or Children’s Health Insurance Program (CHIP) providers who have been... Read More

Blogs & Articles | COVID-19 Resources | Healthcare Law | Medicare and Insurance Audits

CMS Doubles Down On Value Based Care (“VBC”), Taking Additional Comprehensive Measures to Ensure COVID-19 Does Not Disrupt the Continuous and Rapid Transition from Volume Based Care to VBC

Daniel B. Frier, Esq. and Jason N. Silberberg, Esq. June 5, 2020

If there were ever any doubts about the seriousness of CMS’ commitment to transitioning the nation’s healthcare system from one based on volume-based to value-based compensation models, those doubts were squashed by a recent CMS blog post and... Read More

COVID-19 Resources | Healthcare Law | Pharmacy Law | Value Based Care

HHS Provider Relief Funds Assist Healthcare Providers During the COVID-19 Crisis

Marc H. Mayer, Esq. and Daniel B. Frier, Esq. May 6, 2020

$50 Billion in Total Funding Available, But Significant Compliance Requirements Must be Satisfied In mid-April, you may have seen a significant payment from the Federal government mysteriously land in your provider bank account. With little notice... Read More

Blogs & Articles | COVID-19 Resources | Healthcare Law

Provider Alert: Exercise Caution When Operating Under Blanket Waivers of Stark Sanctions

Theresa M. DiGuglielmo, Esq. and John E. Morrone, Esq. May 5, 2020

In response to the COVIDI9 crisis, the Secretary of the Department of Health and Human Services invoked his authority to issue blanket waivers of Section 1877(g) of the Social Security Act (also known as the physician self-referral law or... Read More

COVID-19 Resources | Healthcare Law

Dental Provider Alert: ADA Requests FCC to Support Teledentistry

Theresa M. DiGuglielmo, Esq. and Sarah G. Kim, Esq. May 1, 2020

Since the declaration of a national public health emergency, oral health providers have postponed most non-emergent care, whether as required by state-issued directives, or as recommended by the Interim Guidance for Minimizing Risk of COVID-19... Read More

Blogs & Articles | COVID-19 Resources | Healthcare Law

Toolkit for Healthcare Businesses in Financial Distress

Theresa M. DiGuglielmo, Esq., Sarah G. Kim, Esq. and Daniel B. Frier, Esq. April 29, 2020

As part of our firm’s commitment to staying abreast of COVID19-related issues affecting our clients, we are continuing to monitor financial relief program requirements and other important topics. While applying for various forms of aid and... Read More

FDA Guidance on Conduct of Clinical Trials During the COVID-19 Pandemic

Martha M. Rumore Pharm.D., Esq. and Marc V. Nocera, Esq. April 27, 2020

COVID-19 is having a profound effect on clinical trials for medical products, including drugs, devices and biological products. Site closures, travel restrictions, quarantines, infections among participants and trial personnel, and investigational... Read More

Tag: Coronavirus